One proven cause of unfavorable outcomes in MET altered lung cancer is acquired resistance to EGFR TKIs, underlining the need for more efficient targeted therapies [1,5,6,14,15,17,18,19,20]. The gene discussed is EGFR; the disease is lung carcinoma.